Raymond James Financial
CRVS icon

Raymond James Financial’s Corvus Pharmaceuticals CRVS Stock Holding History

Raymond James Financial’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.46M Sell
99,883
-21,274
-18% -$340K ﹤0.01% 3590
2025
Q4 		$933K Sell
121,157
-3,339
-3% -$26.3K ﹤0.01% 3824
2025
Q3 		$918K Hold
124,496
– – ﹤0.01% 3737
2025
Q2 		$498K Buy
124,496
+16,379
+15% +$59.6K ﹤0.01% 4006
2025
Q1 		$344K Sell
108,117
-872
-0.8% -$4.11K ﹤0.01% 4136
2024
Q4 		$583K Buy
+108,989
New +$814K ﹤0.01% 3806

Other funds holding CRVS

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Raymond James Financial's CRVS Position: Q1 2026 in Review

Raymond James Financial reduced its Corvus Pharmaceuticals (CRVS) stake by 18% in Q1 2026, selling an estimated $340K and leaving 99,883 shares worth $1.46M. The position accounts for ﹤0.01% of the portfolio, ranked #3590.

Raymond James Financial first reported a position in CRVS in Q4 2024 and has held it in 6 quarters since. 164 funds tracked by Wall St. Rank hold CRVS as of Q1 2026.

  • Raymond James Financial held 99,883 shares of Corvus Pharmaceuticals worth $1.46M as of Q1 2026.
  • Raymond James Financial sold 21,274 Corvus Pharmaceuticals shares in Q1 2026, an estimated $340K.
  • Corvus Pharmaceuticals made up ﹤0.01% of Raymond James Financial's portfolio in Q1 2026, its #3590 holding.
  • Raymond James Financial first reported a position in Corvus Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
  • 164 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q1 2026.

Based on Raymond James Financial's 13F filing for Q1 2026, filed 14 May 2026.